论文部分内容阅读
目的观察芪参益气滴丸治疗慢性充血性心力衰竭(CHF)的疗效及安全性。方法将96例CHF患者按数字表法随机分为观察组和对照组,每组48例,两组患者均给予洋地黄、利尿剂、血管紧张素转换酶抑制剂、β-受体阻滞剂、硝酸酯类药物等常规综合治疗,观察组在此基础上加服芪参益气滴丸,疗程均为4周。疗程结束评定疗效、心功能指标及不良反应。结果观察组显效率和总有效率分别为52.1%和97.9%,明显高于对照组的27.1%和85.4%(P<0.01);观察组心排出量、心脏指数、左室射血分数、左室舒张末期容积、左室收缩末期容积等心功能指标较对照组明显改善(P<0.05);两组患者均未出现明显的不良反应。结论芪参益气滴丸能提高CHF患者的临床疗效,改善心功能及预后,且无明显不良反应,是治疗CHF有效、安全的辅助用药,具有广阔的应用前景。
Objective To observe the curative effect and safety of Qishen Yiqi drop pill in treating chronic congestive heart failure (CHF). Methods Ninety-six patients with CHF were randomly divided into observation group and control group according to the digital table method, with 48 patients in each group. The patients in both groups were given digitalis, diuretics, angiotensin converting enzyme inhibitors, β-blockers , Nitrates and other conventional comprehensive treatment, the observation group on this basis plus Qishen Yiqi drop pills, treatment were 4 weeks. End of treatment assessment of efficacy, cardiac function and adverse reactions. Results The effective rate and total effective rate in the observation group were 52.1% and 97.9%, respectively, which were significantly higher than those in the control group (27.1% vs 85.4%, P <0.01). The cardiac output, cardiac index, left ventricular ejection fraction Ventricular end-diastolic volume, left ventricular end-systolic volume and other cardiac function indicators were significantly improved compared with the control group (P <0.05); no significant adverse reactions in both groups. Conclusion Qishenyiqi dripping pills can improve clinical efficacy, improve cardiac function and prognosis of patients with CHF, and no obvious adverse reactions, is an effective and safe adjuvant treatment of CHF, and has broad application prospects.